- Correction
- Open access
- Published:
Correction to: Lenvatinib inhibits the growth of gastric cancer patient‑derived xenografts generated from a heterogeneous populations
Journal of Translational Medicine volume 22, Article number: 842 (2024)
The Original Article was published on 07 March 2022
Following publication of the original article [1], we have been notified that Figure 6c was published incorrectly.
It is now:
Lenvatinib treatment reduced blood vessel density and increased apoptosis in PDX tumors. A H&E and CD31 IHC of vehicle and lenvatinib-treated PDXs (200× magnification) B Intratumoral vascular density quantification. Each dot represents one tumor. The error bar represents the standard error of the mean. C Ki-67 staining of vehicle and lenvatinib-treated tumors. D Ki-67 quantification of vehicle and lenvatinib-treated tumors. Each dot represents the average Ki-67% per PDX line. The error bar represents the standard error of the mean. E TUNEL immunofluorescence staining of vehicle and lenvatinib-treated tumors. F Quantification of TUNEL-positive cells. Each dot represents the average TUNEL-positive cells per PDX line. The error bar represents the standard error of the mean
It should be:
Lenvatinib treatment reduced blood vessel density and increased apoptosis in PDX tumors. A H&E and CD31 IHC of vehicle and lenvatinib-treated PDXs (200× magnification) B Intratumoral vascular density quantification. Each dot represents one tumor. The error bar represents the standard error of the mean. C Ki-67 staining of vehicle and lenvatinib-treated tumors. D Ki-67 quantification of vehicle and lenvatinib-treated tumors. Each dot represents the average Ki-67% per PDX line. The error bar represents the standard error of the mean. E TUNEL immunofluorescence staining of vehicle and lenvatinib-treated tumors. F Quantification of TUNEL-positive cells. Each dot represents the average TUNEL-positive cells per PDX line. The error bar represents the standard error of the mean
The original article was updated.
References
Karalis et al. Lenvatinib inhibits the growth of gastric cancer patient–derived xenografts generated from a heterogeneous population. (2022);20:116. https://doi.org/10.1186/s12967-022-03317-7
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The online version of the original article can be found at https://doi.org/10.1186/s12967-022-03317-7.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Karalis, J.D., Yoon, L.Y., Hammer, S.T.G. et al. Correction to: Lenvatinib inhibits the growth of gastric cancer patient‑derived xenografts generated from a heterogeneous populations. J Transl Med 22, 842 (2024). https://doi.org/10.1186/s12967-024-05632-7
Published:
DOI: https://doi.org/10.1186/s12967-024-05632-7